XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss attributable to Myriad Genetics, Inc. stockholders $ (39.5) $ (115.2)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 18.4 17.9
Non-cash interest expense 0.5 0.1
Non-cash lease expense 3.5 3.0
Gain on deconsolidation of subsidiary 0.0 (1.0)
Gain on disposition of assets (0.3) (0.1)
Share-based compensation expense 9.0 7.5
Deferred income taxes (11.8) (16.0)
Unrecognized tax benefits 0.3 (0.1)
Impairment of goodwill and intangible assets 0.0 98.4
Change in fair value of contingent consideration 0.9 (3.4)
Changes in assets and liabilities:    
Prepaid expenses (2.1) 3.6
Trade accounts receivable (4.7) 15.9
Other receivables (0.4) 1.2
Inventory 2.4 (2.6)
Prepaid taxes 90.3 (0.7)
Other assets (1.2) 0.0
Accounts payable 0.3 9.2
Accrued liabilities 7.8 (1.1)
Deferred revenue (1.6) 0.2
Net cash provided by operating activities 71.8 16.8
CASH FLOWS FROM INVESTING ACTIVITIES    
Capital expenditures (7.1) (3.0)
Proceeds from sale of subsidiary 0.0 21.3
Purchases of marketable investment securities 0.0 (15.8)
Proceeds from maturities and sales of marketable investment securities 15.3 20.7
Net cash provided by investing activities 8.2 23.2
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from common stock issued under share-based compensation plans 26.5 0.3
Payment of tax withheld for common stock issued under share-based compensation plans (0.5) (0.1)
Payment of contingent consideration recognized at acquisition (3.3) 0.0
Fees associated with refinancing of revolving credit facility 1.2 0.0
Repayment of revolving credit facility (70.0) 0.0
Net cash provided by (used in) financing activities (48.5) 0.2
Effect of foreign exchange rates on cash and cash equivalents 0.4 (1.9)
Change in cash and cash equivalents classified as held for sale 0.0 1.5
Net increase in cash and cash equivalents 31.9 39.8
Cash and cash equivalents at beginning of the period 117.0 81.2
Cash and cash equivalents at end of the period $ 148.9 $ 121.0